Inhibiting phosphoinositide 3-kinases.
Samuels
Yardena
Y
The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. ysamuel1@jhmi.edu
Zhu
Jiuxiang
J
Lengauer
Christoph
C
D000730:Androstadienes / Q000494:pharmacology*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D011994:Recombinant Proteins; D015398:Signal Transduction / Q000187:drug effects*; D020123:Sirolimus / Q000627:therapeutic use; D014183:Transplantation, Heterologous; D023041:Xenograft Model Antitumor Assays
D000730:Androstadienes; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011994:Recombinant Proteins; C053480:17-hydroxywortmannin; D051057:Proto-Oncogene Proteins c-akt; D020123:Sirolimus